Both in Pharmaceuticals
UroGen Pharma vs Korsana Biosciences
Over the past year URGN returned −32.1% and KRSA returned −4.2%; their daily moves had a correlation of 0.01.
URGN −32.1% KRSA −4.2%Growth of $1, one year, split-adjusted
| Metric | URGN | KRSA |
|---|---|---|
| Price | $28.74 | $30.56 |
| Market cap | $1.40B | $1.39B |
| Today | −16.45% | −4.38% |
| 1 month | −30.6% | −3.8% |
| 6 months | +9.5% | — |
| Year to date | +22.7% | — |
| 1 year | +39.4% | — |
| Revenue growth (YoY) | +199.2% | — |
| Gross margin | 90.9% | — |
| Net margin | −19.8% | — |
| P/E (TTM) | — | — |
| Price / sales | 7.4× | — |
| Net cash | -$85.1M | — |
| Dividend yield | — | — |
| Volatility (60d) | 54.9% | — |
| Short % of float | 12.3% | 1.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).